💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

Subject: Science and Technology

  • Quantum Supercomputer using Majorana Zero Modes

    majorana

    Central Idea

    • Microsoft researchers have made significant strides in the creation of Majorana zero modes, a type of particle that could revolutionize quantum computing.
    • Majorana zero modes, which are their own antiparticles, possess unique properties that could make quantum computers more robust and computationally superior.

    Majorana Fermions: A conceptual backgrounder

    • Fermions and Antiparticles: All subatomic particles that constitute matter are known as fermions, with each fermion having an associated antiparticle that annihilates upon interaction.
    • Majorana Fermions: In 1937, Italian physicist Ettore Majorana discovered that certain particles, known as Majorana fermions, can satisfy specific conditions and be their own antiparticles.
    • Neutrinos as Potential Majorana Fermions: Neutrinos are one type of subatomic particle that scientists speculate may exhibit Majorana fermion behavior, although experimental confirmation is still pending.

    Understanding Majorana Zero Modes

    • Quantum Numbers and Spin: All particles have four quantum numbers, with one called the quantum spin having half-integer values for fermions. This property allows any fermion, even a large entity like an atom, to be classified as a fermion.
    • Bound States and Fermions: Bound states composed of two particles can also be classified as fermions if their total quantum spin possesses a half-integer value.
    • Majorana Zero Modes: When these bound states are their own antiparticles and do not readily de-cohere, they are known as Majorana zero modes, which have been sought after by physicists for many years.

    Easy explained: Majorana Zero Modes

    In the world of physics, particles can have interesting properties and behave in strange ways. One type of particle that scientists have been studying is called a Majorana particle.

    Majorana particles have a special property called “non-Abelian statistics.” Without getting too technical, this property means that when two Majorana particles come close together, something interesting happens. Instead of behaving like normal particles, they can combine in a special way to form a new kind of particle called a Majorana zero mode.

    A Majorana zero mode is a very peculiar particle because it is its own antiparticle. Normally, particles have antiparticles with opposite properties, like an electron and a positron. But Majorana zero modes are special because they don’t have separate antiparticles. They are their own antiparticles!

    Potential Benefits for Computing

    • Enhanced Stability: Majorana zero modes offer increased stability for qubits, the fundamental units of information in quantum computing. Even if one entity within the bound state is disturbed, the qubit as a whole can remain protected and retain encoded information.
    • Topological Quantum Computing: Majorana zero modes can enable topological quantum computing, which takes advantage of non-Abelian statistics. These statistics introduce an additional degree of freedom, allowing algorithms to produce different outcomes based on the order in which steps are performed.

    Challenges and Future Prospects

    • Creating Majorana Zero Modes: Scientists have been exploring various setups, such as topological superconductors, to generate Majorana zero modes. However, confirming their existence remains a challenge, as their effects on surrounding materials must be inferred indirectly.
    • Recent Advances by Microsoft Researchers: Microsoft researchers recently engineered a topological superconductor using an aluminium superconductor and an indium arsenide semiconductor. Their device passed a stringent protocol, suggesting a high probability of hosting Majorana zero modes.

    Future prospects

    • While this achievement is significant, the existence of Majorana fermions and their potential for topological quantum computing still need independent confirmation.
    • Continued improvements in simulation, growth, fabrication, and measurement capabilities are necessary to achieve the desired topological gap for coherent operations.

  • AI’s disruptive economic impact, an India check

    AI

    What is the news?

    • The rise of Artificial Intelligence (AI) and generative AI models and its impact on productivity, growth, and employment is explored, with a focus on the positive effects, potential job displacement, and opportunities for India, while dispelling fears of a robot-dominated future.

    Central Idea

    • The rapid advancements in AI, particularly in the form of Large Language Models and Generative AI, have revolutionized various aspects of our lives. From automated factories to self-driving cars and chatbots, AI has extended its influence beyond our expectations.

    What is Artificial Intelligence?

    • AI is a constellation of technologies that enable machines to act with higher levels of intelligence and emulate the human capabilities of sense, comprehend and act.
    • An AI system can also take action through technologies such as expert systems and inference engines or undertake actions in the physical world.
    • These human-like capabilities are augmented by the ability to learn from experience and keep adapting over time.

    What is generative AI?

    • Like other forms of artificial intelligence, generative AI learns how to take actions from past data.
    • It creates brand new content – a text, an image, even computer code – based on that training, instead of simply categorizing or identifying data like other AI.
    • The most famous generative AI application is ChatGPT, a chatbot that Microsoft-backed OpenAI released late last year.
    • The AI powering it is known as a large language model because it takes in a text prompt and from that writes a human-like response.

    Potential positive economic impact of AI

    • PwC Report: The PwC report predicted an increase in global GDP by 14% or $15.7 trillion by 2030 due to ongoing technological advancements in AI. It also suggests that the greatest economic gains from AI will come from China, with a projected 26% boost to GDP by 2030.
    • Goldman Sachs Research: According to the Goldman Sachs Research report, generative AI alone could raise global GDP by 7% or almost $7 trillion over a 10-year period.
    • Forum for the Kent A. Clark Center for Global Markets Survey: The survey conducted among economic experts revealed that 44% of U.S. experts expected a substantial increase in GDP per capita due to AI, while 34% of European experts expected the same.

    Positive effects of AI adoption

    • Increased productivity: A study conducted by economists from the Massachusetts Institute of Technology (MIT) called Generative AI at Work revealed that AI tools improved worker productivity by 14% and enhanced consumer satisfaction among customer service agents.
    • Improved consumer satisfaction: AI tools have contributed to better treatment of customer service agents, leading to improved consumer satisfaction.
    • Employee retention: The use of AI tools in the workplace has been associated with increased employee retention rates, possibly due to the enhanced productivity and job satisfaction resulting from AI support.
    • Faster and smarter work: A recent survey among employees of LinkedIn’s top 50 companies in the United States shows that almost 70% of them found AI helping them to be faster, smarter, and more productive
    • Potential for significant GDP growth: Research by PwC suggests that ongoing advancements in AI could lead to a projected increase in global GDP by 14% or $15.7 trillion by 2030.
    • Creation of human-like output: Generative AI has the potential to generate human-like output, which can have positive macroeconomic effects by facilitating better communication and interaction between humans and machines.

    Employment challenges

    • Labor replacement: AI technologies have the capability to automate both repetitive and creative tasks, potentially leading to the displacement of certain jobs.
    • Negative impact on wages and employment: Studies indicate that the adoption of robots and automation can have a negative effect on wages, employment, and the labor share. This impact is particularly observed among blue-collar workers and those with lower levels of education.
    • Wage inequality: Automation and AI contribute to wage inequality by affecting worker groups specializing in routine tasks. Changes in the wage structure over the last few decades can be attributed to the decline in wages for workers engaged in routine tasks in industries undergoing automation.
    • Intensified competition and winner-takes-all scenario: The adoption of AI may intensify competition among firms, potentially leading to a winner-takes-all scenario where early adopters gain significant advantages.
    • Displacement of middle-class jobs: AI technologies, especially in white-collar industries, may displace middle-class jobs, posing challenges for those in such occupations. The impact of AI on middle-class employment remains uncertain, potentially leading to job losses in these sectors.

    Opportunities for India

    • Embracing the demographic dividend: India’s large population presents an opportunity to leverage the demographic dividend. By investing in AI education and training, India can harness the potential of its workforce and utilize AI to drive economic growth and create employment opportunities.
    • Focus on online education: The pandemic has increased acceptance and reliance on online education. India can take advantage of this trend and utilize online platforms to offer AI education and reach a wider audience, further accelerating the adoption of AI skills across the country.
    • Potential economic gains: The PwC report suggests that China is projected to experience the greatest economic gains from AI. However, India can still benefit by focusing on AI education, innovation, and creating an ecosystem that fosters AI-driven growth. By doing so, India can tap into the economic benefits associated with AI and boost its own GDP.

    Way forward

    • Collaborative approach: Governments, industry, academia, and civil society should collaborate to shape the future of AI in a manner that benefits society as a whole. Open dialogues, partnerships, and knowledge sharing can drive responsible AI development.
    • Lifelong learning: Promoting a culture of lifelong learning and continuous skill development is crucial. This includes investing in education and training programs that cater to the changing demands of the AI-driven job market.
    • Regulatory frameworks: Governments need to develop agile regulatory frameworks that strike a balance between innovation and accountability. These frameworks should be adaptable to evolving technologies and address potential risks associated with AI.
    • Research and innovation: Continued research and investment in AI can drive innovation, especially in areas such as explainable AI, ethics, and responsible AI practices. Encouraging interdisciplinary collaboration and supporting AI research can lead to breakthroughs in addressing challenges and maximizing benefits.
    • Inclusive approach: Ensuring inclusivity in AI development and deployment is vital. Diversity in AI teams and the inclusion of diverse perspectives can help mitigate biases and ensure AI systems serve the needs of all individuals and communities.

    Conclusion

    • Artificial Intelligence has permeated various sectors of the global economy, offering substantial benefits in terms of productivity and growth. While concerns regarding job displacement persist, the full extent of AI’s impact on employment remains uncertain. Governments should proactively address the challenges posed by AI while promoting education and training in AI-related fields.

    Also read:

    Artificial Intelligence (AI) in Healthcare: Applications, Concerns and regulations

  • LVM-3: the ISRO Rocket

    lvm

    Central Idea

    • ISRO is scheduled to launch the Chandrayaan 3 mission on July 14.
    • The mission will be carried out using the LVM-3 configuration.
    • The GSLV is used for heavier payloads and higher orbits, with the most powerful configuration known as LVM-3.
    Soon a comprehensive article about Chandrayaan 3 would be released!

     

    LVM3: Unlocking New Frontiers of Space Exploration

    • Expendable Space Launch Vehicle: LVM3 is an expendable space launch vehicle meticulously crafted by ISRO.
    • Purpose: Its primary objective is to deploy satellites and space objects into Geosynchronous Transfer Orbits (GTO).
    • Launch History: ISRO successfully launched the first LVM3 on April 18, 2001, and has accomplished a total of 13 launches to date.
    • Impressive Specifications: With a lift-off mass of 420 tonnes, LVM3 demonstrates its robustness in handling complex missions.

    Stages of LVM3: Powering the Journey to Orbit

    First Stage:

    • S139 Solid Booster: The initial stage of LVM3 features the S139 solid booster, armed with 138 tonnes of propellant.
    • Liquid Strap-on Motors: Additionally, it incorporates four liquid strap-on motors, each carrying 40 tonnes of propellant.

    Second Stage:

    • Liquid Engine: The second stage of LVM3 is equipped with a liquid engine, propelling the vehicle with 40 tonnes of liquid propellant.

    Third Stage:

    • Cryogenic Upper Stage (CUS): LVM3 showcases its technological prowess with the indigenously built CUS, capable of accommodating 15 tonnes of cryogenic propellants.

    Back2Basics: Sattelite Launch Vehicles

    slv

  • The challenge of Antimicrobial Resistance (AMR), and how to confront it effectively

    What’s the news?

    • Antimicrobial Resistance (AMR) is today reckoned among the most ominous threats confronting Global Public Health. There is an urgent need for a collective and comprehensive approach to address the global threat of AMR and the role of various stakeholders in prevention, control, and surveillance efforts is crucial.

    Definition

    • Antimicrobial resistance, means that certain drugs that were once effective in treating infections caused by bacteria, viruses, fungi, or parasites no longer work because the pathogens have become resistant to them.
    • In simpler terms, it is when the germs that make us sick become “immune” to the medicines we use to treat them.

    Prevalence of AMR

    • According to recent estimates, in 2019, 1.27 million deaths were directly attributed to drug-resistant infections globally. By 2050, up to 10 million deaths could occur annually.
    • If unchecked, AMR could shave US$ 3.4 trillion off GDP annually and push 24 million more people into extreme poverty in the next decade.
    • A 2022 study by the Indian Council of Medical Research (ICMR) revealed that resistance to broad-spectrum antimicrobials increases by 5% to 10% every year.

    AMR: A concern for global public health

    • Rising Resistance: The infections caused by the pathogens including bacteria, viruses, fungi, and parasites, are increasingly developing resistance to antimicrobial drugs which is becoming more challenging to treat effectively.
    • Treatment Failures: AMR can lead to treatment failures, as commonly used antibiotics, antivirals, antifungals, and antiparasitic drugs may no longer be effective against resistant strains.
    • Healthcare Impact: AMR increases the complexity and cost of treatment, prolongs hospital stays, and requires the use of stronger and more expensive drugs. Healthcare-associated infections caused by drug-resistant pathogens are a particular concern.
    • Limited Drug Pipeline: The development of new antimicrobial drugs has slowed down in recent years. There is a lack of new effective treatments to replace those that are losing effectiveness due to resistance.
    • Global Spread: AMR is a global issue that knows no boundaries. Resistant pathogens can spread between countries through travel and trade, and international cooperation is crucial.

    Current Scenario of AMR prevention and National Action Plans

    • Over the last ten years, the prevention, control, and response to AMR has been a high priority for most national governments, international organisations (such as the WHO, FAO, OIE), healthcare communities, and civil society, etc.
    • The WHO’s global action plan (GAP) was adopted by member nations in 2015.
    • National action plans have been prepared by many countries.
    • India’s NAP was approved in 2017. It is understood that NAP 2.0 is now envisaged.
    • In 2015, the WHO launched the Global Action Plan (GAP) on AMR, which provides a strategic framework for countries to develop their national action plans.
    • AMR is an important priority in the G20 health agenda under India’s presidency.

    India’s national action plan to combat AMR

    • Coordinated Action: India’s NAP emphasizes coordinated action by the government and non-government sectors. It involves a whole of government approach, involving sectors like Health, Animal Husbandry, Fisheries, Agriculture, Dairy, Pharmaceuticals, and Biotechnology.
    • Advocacy and Awareness: The plan focuses on advocacy and awareness-building activities to educate healthcare professionals, policymakers, and the general public about responsible antimicrobial use and AMR prevention.
    • Community Involvement: India’s NAP It emphasizes engaging and empowering communities to promote responsible use of antimicrobials.
    • Infection Prevention and Control: The NAP emphasizes infection prevention and control measures to reduce the spread of AMR. This includes promoting appropriate hygiene practices and implementing infection control protocols in healthcare settings.
    • National AMR Surveillance Network (NARS Net): India has established the National AMR Surveillance Network to monitor and track the prevalence and patterns of AMR across the country. This surveillance system helps in generating data for evidence-based interventions.
    • Research and International Collaboration: India’s NAP emphasizes the importance of research on AMR and encourages international collaboration in this field.

    Need for a concerted, combined effort to address AMR

    • One Health Approach: AMR requires a One Health approach, recognizing the interconnectedness of human health, animal health, and the environment. Collaborative efforts among human and veterinary healthcare sectors, agriculture, environmental agencies, and other stakeholders are necessary to tackle AMR comprehensively.
    • Stakeholder Involvement: The sectors responsible for food, drinking water, and the environment should share equal ownership in addressing AMR. Regulating antibiotic access and usage in non-human consumption sectors, such as animal husbandry and poultry, is vital.
    • State and Local Engagement: Implementation of infection control measures, regulation of pharmacies, treatment of sewage and pharmaceutical effluents, and AMR surveillance are primarily implemented at the state level.
    • Environmental Considerations: Efforts should be made to prevent the contamination of the environment by untreated wastewater and effluents, including those from antibiotics manufacturing units and healthcare facilities. Effective sanitation and waste treatment infrastructure are necessary to combat AMR.
    • Surveillance and Data: Robust surveillance systems are crucial to monitor AMR patterns and trends. Collecting and analyzing data on antimicrobial use, resistance prevalence, and treatment outcomes helps inform evidence-based interventions.

    What’s more?

    • Parallel efforts on a war footing are needed for the discovery and commercialisation of new antibiotics and new antimicrobials. Such efforts must be incentivised.
    • Social media and its numerous platforms have captured the imagination of people around the world. The influence of social media on our mind and behaviour cannot be denied. We
    • Considering its influence on our mind and behaviour, social media and its numerous platforms must be leveraged to spread the message of AMR.
    • Objective should be to inculcate community realisation for rational and correct use of antimicrobials.

    Conclusion

    • Addressing the global challenge of AMR demands a collective and coordinated effort involving various stakeholders. Embracing novel solutions, such as new diagnostics, alternative treatments, and technology-driven interventions, is essential. By embracing these measures, we can protect public health, alleviate economic burdens, and secure a healthier future for all.

    Also read:

    Antimicrobial Resistance (AMR): An Invisible Pandemic

  • Solar Shooting Stars: Discovering Fiery Rain on the Sun

    shooting star

    Central Idea

    • Astronomers have made a remarkable discovery of meteor-like streaks on the surface of the Sun, differentiating them from the shooting stars witnessed on Earth.
    • These solar shooting stars, observed during a phenomenon known as coronal rain, offer valuable insights into the Sun’s complex dynamics.

    Observing Coronal Rain and Solar Shooting Stars

    • Distinction from Earthly Shooting Stars: While shooting stars on Earth are space rocks or dust fragments burning up in our atmosphere, solar shooting stars occur within coronal rain phenomena.
    • Coronal Rain: Coronal rain is a condensation process involving extremely hot material from the Sun’s corona. It forms dense clumps of plasma, which plummet back to the Sun’s surface due to its immense gravity.
    • European Space Agency’s Solar Orbiter (SolO): The SolO spacecraft provided valuable observations of solar shooting stars, capturing high-resolution images and monitoring the heating and compression of gas beneath them.

    Characteristics of such Stars

    • Findings: The Solar Orbiter observed the impacts of solar shooting stars for the first time, revealing intense bursts of brightness, upward movement of stellar material, and shock waves that heat up the Sun’s corona.
    • Unique Features: Unlike Earthly shooting stars, solar shooting stars lack bright tails due to powerful magnetic fields in the Sun’s corona stripping gas from the falling clumps.
    • Challenging Observations: The magnetic fields’ influence makes the observation of solar meteors challenging, and their true nature remained unknown until these recent observations.

    Insights and Implications

    • Solving the Corona Mystery: Scientists believe that the discovery of solar shooting stars could help explain why the corona, the Sun’s outermost atmosphere, is hotter than the layers beneath it. This puzzles astronomers, as conventional solar models predict increasing temperatures closer to the Sun’s core.
    • Coronal Rain Formation: Coronal rains are formed by localized temperature drops, causing solar plasma to condense into dense lumps that fall to the Sun’s cooler surface, known as the photosphere, at speeds up to 220,000 miles per hour.
    • Proximity of Observation: The Solar Orbiter’s close distance of 30 million miles from the Sun allowed for detailed observations of these phenomena, closer than the orbit of Mercury.

  • Bio-Banks

    biobanks

    Central Idea

    • The biotechnology economy, commonly known as the bioeconomy, has experienced significant growth in recent years, driven by advancements in genetic research, healthcare applications, and innovations in food security and bioproduction. However, the responsible collection, storage, and sharing of biological data, particularly in the form of biobanks, necessitate robust governance to ensure equitable access and benefit sharing.

    *Relevance of the topic*

    India’s participation in healthcare advancements, including vaccine development and deployment, highlights its potential in the bioeconomy.

    The pharmaceutical industry, coupled with expertise in medical research, positions India as a global leader in healthcare innovation and the production of drugs and therapies.

    Considering its vast populations and challenges in healthcare, personalised healthcare is the need of the hour which makes biobanks is crucial factor for India

    What is the biotechnology economy?

    • The biotechnology economy, also known as the bioeconomy, refers to the sector that encompasses various activities related to biotechnology, genetic research, and the utilization of biological resources for industrial and commercial purposes.
    • It encompasses the application of biological knowledge, principles, and techniques to develop innovative products, processes, and services in sectors such as healthcare, agriculture, food production, energy, environmental conservation, and more.
    • The biotechnology economy relies on advancements in genetic engineering, genomics, bioinformatics, and other fields to understand and manipulate biological systems for practical purposes.
    • It involves the development of new drugs, therapies, and medical treatments, the improvement of agricultural crops and livestock, the production of biofuels and renewable materials, and the creation of sustainable solutions for various industries.

    India’s potential in the Bioeconomy

    • Bioeconomy Market Value: India’s Bioeconomy Report projects a potential market value of US$300 billion for the bioeconomy in India by 2030. This indicates significant growth and economic prospects in the sector.
    • Biotech Start-up Growth: The number of biotech start-ups in India has witnessed exponential growth, increasing from 50 to over 5,300 in the last ten years. This thriving ecosystem reflects a robust foundation for research, development, and industrial participation in the bioeconomy.
    • Biobanking Landscape: India currently hosts 19 registered biobanks out of a total of 340 global biobanks. This infrastructure plays a crucial role in the collection, preservation, and sharing of biological data for research and development purposes.

    Significance of biobanks for India

    • Medical Research and Advancements: Biobanks store biological samples, such as blood, tissue, and DNA, along with associated health information. These samples and data enable researchers to study diseases, understand genetic factors, identify biomarkers, and develop new diagnostic tools and therapies.
    • Disease Understanding and Treatment: By collecting samples and health information from individuals with specific diseases or genetic conditions, biobanks facilitate research on disease etiology, progression, and treatment options.
    • Precision Medicine and Personalized Healthcare: By analyzing genetic and molecular data stored in biobanks, researchers can identify individual variations and develop tailored treatment approaches based on a person’s unique genetic makeup.
    • Public Health and Epidemiology: By analyzing large-scale data sets from biobanks, researchers can identify risk factors, understand disease prevalence, monitor disease trends, and develop strategies for disease prevention and public health interventions.
    • Drug Development and Clinical Trials: Biobanks play a crucial role in drug development and clinical trials. They provide researchers and pharmaceutical companies with access to well-characterized biological samples and associated health data, which are essential for evaluating drug efficacy, safety, and side effects.

    Inequitable Data Collection and Benefit Deployment

    • Global South Underrepresentation: The the majority of biobanks are housed in North America and Europe, covering about 95 percent of the biobanks globally. In contrast, the Global South, including India, only hosts approximately 5 percent of the world’s biobanks. This underrepresentation limits the Global South’s participation in health research and the deployment of health initiatives.
    • Research Bias: Due to the concentration of biobanks in the Global North, there is a bias in research and funding, focusing on genetic conditions and diseases that are prevalent in those regions. This bias hamper research on health challenges specific to the Global South, limiting the relevance and applicability of the findings to the populations in these regions.
    • Dissonance in Results: There is a dissonance in using samples from the Global South to cater to health requirements primarily in the Global North. This dissonance implies that research outcomes derived from data collected in the Global South may not adequately address the healthcare needs and challenges faced by the populations in that region.
    • Lack of Equitable Benefit Sharing: The lack of explicit return on results policies leads to inadequate sharing of benefits derived from the data collected in the Global South. The benefits and outcomes of research conducted using biobank data from the Global South are not shared equitably among the countries and populations from which the data originated.
    • Inequities During the Pandemic: The article cites an example of inequity during the COVID-19 pandemic, where the capacity of Afrigen, a biotech firm responsible for vaccine production in Cape Town, was limited due to the desire of private sector participants like Moderna and Pfizer to preserve their knowledge. This resulted in Africa’s reliance on global vaccine manufacturing, with only 1 percent of vaccines consumed on the continent being manufactured within Africa.

    India’s contributions and leadership in the bioeconomy

    • Healthcare and Vaccine Development: India has actively contributed to healthcare and vaccine development. The country has been involved in SARS-CoV-2 vaccine development, deployment, and diplomacy. Its expertise and participation have played a crucial role in addressing global health challenges.
    • Global South Representation: India’s involvement in advocating for global South representation in biobanking governance and global platforms demonstrates its commitment to addressing inequities. India’s leadership contributes to fostering collaboration, trust, and fair participation among countries in the Global South.
    • Multilateral Engagement: India’s association with the Quadrilateral Alliance and its G20 presidency provide platforms for global diplomacy and collaboration. These engagements enable India to advocate for global governance structures and mechanisms that promote equitable access, benefit sharing, and funding in the bioeconomy.
    • National Guidelines and Best Practices: India has established guidelines and best practices for biobanking, ethical data storage, sharing, and benefit distribution. The Department of Biotechnology and the Ministry of Science and Technology have played key roles in formulating these guidelines, ensuring responsible practices in the bioeconomy.
    • Exporting Health Information and Data: India has a history of exporting health information and data, which positions it as a contributor to global health initiatives. Leveraging its experience, India can emphasize the prioritization of diseases relevant to the Global South, prevent biopiracy, and establish rules for benefit sharing to benefit countries in these regions.
    • Global Diplomacy and Platforms: India’s involvement in global platforms, such as the G20 presidency, has enabled it to expand its national regulations and contribute to the establishment of a global governance structure for biobanking and data sharing. This allows India to advocate for relief from trust issues, mechanisms for benefit sharing, and incentives for funding in the Global South.

    Way forward: Addressing Inequities through Global Governance

    • Global South Representation: There is a need for greater representation of the Global South in global governance structures. This ensures that the specific requirements and perspectives of the Global South are considered in decision-making processes and policies.
    • Global Guidelines for Biobanking: There is need of the formulation of global guidelines for biobanking to establish standards and best practices. These guidelines would address ethical data collection, storage, sharing, and benefit distribution, taking into account the specific needs and concerns of the Global South.
    • Equitable Benefit Sharing: It is important to explicit return on results policies to ensure equitable benefit sharing. These policies would ensure that the benefits derived from data collected in the Global South are shared back with the countries and populations from which the data originated.
    • Collaboration and Knowledge Exchange: Global governance in the bioeconomy should foster collaboration, knowledge exchange, and technology transfer between countries and regions. This collaboration helps address disparities, build trust, and promote capacity-building efforts in the Global South.
    • Addressing Obstacles and Barriers: Global governance should address obstacles and barriers to data hosting, collection, and sharing in the Global South. This may include financial constraints, technological limitations, and infrastructure gaps that hinder effective participation and contribution.
    • Private Sector Engagement:  It is essential to define the role of the private sector in research and emergencies. Global governance should encourage responsible and ethical private sector engagement, fostering investment, innovation, and knowledge sharing in the Global South.

    Conclusion

    • The promotion of equitable governance in biobanking is crucial for advancing scientific research, ensuring equitable healthcare, and addressing the unique healthcare challenges faced by the global South. The time is ripe for India to champion this cause and drive transformative change in the field of biobanking on a global scale.

    Also read:

    Mainstreaming Biodiversity: A Pivotal Step Towards a Sustainable Future

  • Tomato Crop affected by different Mosiac Viruses

    tomato mosiac

    Central Idea

    • Tomato growers in Maharashtra and Karnataka have reported significant yield losses due to the impact of two different Mosiac Viruses.
    • The cucumber mosaic virus (CMV) has affected tomato crops in Maharashtra, while the tomato mosaic virus (ToMV) has been blamed for crop losses in Karnataka and other South Indian states.

     

    Cucumber Mosaic Virus (CMV)

    Tobacco Mosaic Virus (TMV)
    Target Plants Various plants, including cucumbers, tomatoes, peppers, lettuce, and ornamentals Plants in the Solanaceae family, including tobacco, tomatoes, peppers, etc.
    Transmission Aphids, seeds, mechanical contact, infected plant debris Direct contact, mechanical transmission, contaminated plant material
    Symptoms Mosaic patterns, yellowing, stunted growth, leaf curling, distorted fruits or flowers Mosaic patterns, yellowing, leaf curling, stunted growth
    Impact on Crops Reduced yield and quality Reduced yield, impact on flavor and quality
    Longevity Not specified Long-term viability in dried plant debris, tobacco products, contaminated surfaces
    Control Measures Vector control, seed selection, crop rotation Crop rotation, sanitation, virus-free seeds/seedlings, cultural practices
    Curability No cure, management focuses on prevention No cure, management focuses on prevention

     

    Impact on Tomato Crops

    • Symptoms of ToMV: Infected plants exhibit alternating yellowish and dark green areas, blisters on leaves, leaf distortion, twisting of younger leaves, necrotic spots on fruits, and reduced fruit setting.
    • Symptoms of CMV: Leaf distortion, with top and bottom leaves most affected, mosaic-like patterns of yellow and green spots in cucumber, fruit deformation, and reduced production in tomato.

    Control Measures

    • ToMV: Ensuring biosafety standards in nurseries, seed treatment, careful inspection of saplings before planting, continuous monitoring for infection, and removal of infected plants are crucial.
    • CMV: Due to its wide host range, controlling aphids becomes essential. Measures include spraying quick-acting insecticides or mineral oils, monitoring aphid migration, and clearing fields of weeds and plant material that may harbor the virus.

     

  • Where India lags in science, research fields, and can National Research Foundation help fix it?

    Central Idea

    • The government’s recent approval of the National Research Foundation (NRF) has been widely hailed by the scientific community in India. The establishment of the NRF presents a significant opportunity to tackle long-standing deficiencies within the country’s scientific research sector.

    *Relevance of the topic

    *Despite possessing a vast pool of science and engineering graduates, extensive research institutions, and active involvement in cutting-edge scientific research, India has lagged behind several nations in research indicators.

    *While the spending on research has increased over the years, it has not kept pace with the rapid growth of India’s GDP.

    *It is crucial for India to harness the potential of demographic dividend

    Insufficient expenditure on research and development

    • Inadequate Allocation: The Indian government has failed to meet its stated objective of allocating at least two percent of the national GDP for research and development (R&D) activities. Despite this objective being set for over two decades, the current expenditure on research as a proportion of GDP stands at only around 0.65 percent, a decline from 0.8 percent at the beginning of the millennium.
    • Stagnant Growth: The share of research expenditure as a percentage of GDP has remained stagnant for the past decade, indicating a lack of significant progress in increasing investment in R&D.
    • Falling Behind Global Standards: In comparison to other countries, India’s expenditure on R&D falls short. According to the 2021 UNESCO Science Report, at least 37 countries spent more than one percent of their GDP on R&D in 2018, with 15 of them surpassing the two percent mark. Globally, the average percentage of GDP spent on R&D is 1.79 percent, indicating that India lags behind in research investment.
    • Insufficient Funding per Researcher: The amount allocated per researcher in India is significantly lower compared to other nations. In 2020, India spent only $42 (in purchasing power parity terms) per researcher. In contrast, countries like Israel, South Korea, and the United States invested substantially higher amounts per researcher, highlighting the need for increased financial support to facilitate quality research.
    • Disproportionate Growth: While funding for research in India has increased over the years, it has not kept pace with the country’s economic growth. As a result, the share of research expenditure as a proportion of GDP has declined, indicating a mismatch between the growth of the research sector and overall economic development.

    Significance of sufficient allocation for research and development (R&D) activities in India

    • Promoting Innovation and Technological Advancement: Adequate funding for R&D fosters innovation and technological advancement in various sectors. It allows scientists, researchers, and institutions to conduct groundbreaking research, develop new technologies, and create intellectual property.
    • Addressing Societal Challenges: Sustained investment in R&D enables the exploration of solutions to pressing societal challenges. It supports research in areas such as healthcare, agriculture, energy, climate change, and infrastructure development.
    • Enhancing Global Competitiveness: Adequate funding for R&D is crucial for India to remain globally competitive. It allows the country to stay at the forefront of scientific advancements, technological breakthroughs, and innovation. By investing in R&D, India can nurture a skilled workforce, attract talent, foster collaborations with international partners, and build a strong knowledge-based economy.
    • Driving Economic Growth and Job Creation: R&D stimulates demand for goods and services, creates employment opportunities, and contributes to overall economic development. Robust R&D investment promotes entrepreneurship, encourages startups, and facilitates the commercialization of research outcomes, leading to job creation and economic prosperity.
    • Strengthening Academic Institutions: Sufficient allocation for R&D enables universities and research institutions to enhance their research infrastructure, attract top talent, and engage in cutting-edge research. This strengthens the academic ecosystem, promotes interdisciplinary collaboration, and facilitates knowledge transfer between academia and industry.
    • Leveraging Global Collaboration: Adequate investment in R&D enables India to actively participate in global collaborations and leverage international expertise. It encourages knowledge sharing, joint research projects, and scientific collaborations with renowned institutions worldwide.

    India’s research output and collaboration

    • Doctorates and Research Output: India produces a significant number of science and engineering doctorates. In the year 2020-21, India produced 25,550 doctorates, with 14,983 in science and engineering disciplines. In terms of absolute numbers, India ranks among the top countries globally. However, considering India’s large population, the number of researchers per million is relatively low compared to other developing nations.
    • Publications: Indian researchers have shown improvement in publishing articles in international science and engineering journals. In 2020, they published 149,213 articles, which is almost two and a half times more than a decade earlier. However, Indian publications only constituted 5 percent of all articles published globally. China contributed 23 percent, while the United States accounted for 15.5 percent.
    • Patents: In 2021, India filed a total of 61,573 patents, making it the sixth-largest in the world in terms of patent filings. However, this number is significantly lower compared to countries like China and the United States, which filed millions of patents in the same year.

    Necessity of National Research Foundation (NRF)

    • Addressing Funding Issues: The NRF has the potential to address the issue of insufficient funding for research and development (R&D) activities in India. By providing a centralized funding mechanism, the NRF can streamline and optimize the allocation of resources, ensuring that sufficient funds are directed towards scientific research.
    • Coupling Education and Research: One of the key areas where India faces an anomaly is the disconnect between education and research. The NRF places emphasis on rectifying this by coupling education and research.
    • Strengthening Research in Universities: The NRF aims to enhance research capabilities in universities. Currently, only a small percentage of Indian universities engage in active research. The NRF’s focus on rectifying this anomaly can lead to the establishment of robust research ecosystems within universities, making them centres for research and development activities.
    • Promoting Collaboration and Innovation: By providing a platform for interdisciplinary collaborations, facilitating knowledge-sharing, and encouraging industry-academia partnerships, the NRF can foster innovation, accelerate the translation of research outcomes into practical applications, and promote entrepreneurship.
    • Addressing Gender Disparity: The NRF can also contribute to addressing the gender disparity in the scientific research sector. By prioritizing gender diversity and inclusivity in research funding and initiatives, the NRF can work towards increasing the representation of women in scientific research, fostering an environment that is more equitable and diverse.

    Conclusion

    • The establishment of the National Research Foundation holds tremendous promise for rectifying deficiencies in India’s scientific research sector. It is imperative for the government, scientific community, and relevant stakeholders to collaborate and provide the necessary support to ensure the success of the NRF in transforming India’s research landscape

  • Leptospirosis: A disease that surges in monsoons

    lepto

    Central Idea

    • Leptospirosis has emerged as an important infectious disease in the world today.
    • It is a potentially fatal zoonotic bacterial disease that tends to have large outbreaks after heavy rainfall or flooding.

    What is Leptospirosis?

    • Leptospirosis is a zoonotic bacterial disease that poses a significant global health threat, particularly after heavy rainfall or flooding.
    • It affects millions of people annually, with a high mortality rate, and its burden is expected to increase in the future.
    • The disease is caused by the bacterium Leptospira interrogans, primarily transmitted from animals to humans.

    Disease Transmission and Risk Factors

    • Disease transmission: Leptospira is shed in the urine of infected animals, contaminating soil and water.
    • Carriers: Both wild and domestic animals, including rodents, cattle, pigs, and dogs, can transmit the disease.
    • Human exposure: Direct contact with animal urine or indirectly through contaminated soil and water poses a risk.
    • Occupational hazards: Agricultural workers, animal handlers, and those in sanitary services are at an increased risk.
    • Recreational activities: Engaging in water-based activities in contaminated lakes and rivers can also raise the risk.

    Symptoms and Misdiagnosis

    • Range of symptoms: Leptospirosis symptoms vary from mild flu-like illness to life-threatening conditions affecting multiple organs.
    • Misdiagnosis challenges: Symptoms mimic other diseases like dengue, malaria, and hepatitis, leading to underreporting and limited awareness.
    • Limited access to diagnostics: Lack of reliable diagnostic tools hinders accurate disease detection.
    • Lack of environmental surveillance: Insufficient monitoring of the environment contributes to underestimating the disease burden.

    Misconceptions and Preventive Measures

    • Reservoir hosts: Rats are not the sole cause; various animals act as reservoir hosts.
    • Environmental factors: Humidity and extreme weather events like floods increase the risk of exposure.
    • Sanitary conditions: Poor waste management, high density of stray animals, and inadequate sanitation facilities contribute to the disease spread.
    • Prevention strategies: Adopting a ‘One Health’ approach involving humans, animals, and the environment is crucial.
    • Personal protective equipment: People working with animals or in flooded areas should use gloves and boots.
    • Animal health and prevention: Ensuring sanitary animal-keeping conditions reduces the risk of leptospirosis transmission.
    • Health education and awareness: Promoting proper hygiene practices, educating about the disease, and improving health literacy are essential preventive measures.

     

  • Antibiotics with promise — a lifeline India awaits

    Central Idea

    • The battle against highly drug-resistant infections has reached a critical stage, where the need for effective antibiotics cannot be overstated. In a recent incident, a team of doctors encountered a challenging situation that showcased the critical importance of taking immediate action.

    Relevance of the topic

    Relate it with the antimicrobial resistance (AMR). AMR often also called antibiotic resistance, is a global health challenge and a looming public health crisis.

    The Case of Extensively Drug Resistant Pseudomonas aeruginosa

    • In an intensive care room, a brave 18-year-old patient fought not only T-cell leukemia but also an aggressive and resistant strain of Pseudomonas aeruginosa.
    • With limited treatment options due to the bacterium’s high resistance to antibiotics, the patient’s condition deteriorated rapidly.
    • The infection attacked his lungs, resulting in persisting fever spikes and severe damage to his face. Time was running out, and his life hung in the balance.

    Indian Innovation in antibiotic development

    • Effective Combination: Cefepime/zidebactam is an innovative antibiotic developed by Indian researchers. It combines two active components to combat drug-resistant gram-negative pathogens, including the formidable Pseudomonas aeruginosa.
    • Promising Results: This Indian innovation has shown remarkable potential in combating highly drug-resistant infections. It has undergone phase 3 trials internationally, demonstrating its effectiveness and safety profile.
    • Compassionate Use: In a compelling case, an 18-year-old patient suffering from T-cell leukemia and an extensively drug-resistant strain of Pseudomonas aeruginosa experienced a miraculous recovery after receiving cefepime/zidebactam under a compassionate use protocol. This highlights the life-saving impact of this innovative antibiotic.
    • Urgent Need for EUA: The extraordinary case of the patient’s recovery emphasizes the urgent need for Emergency Use Authorization (EUA) for antibiotics like cefepime/zidebactam that have shown promising results in phase 3 trials or have been licensed from other countries. Granting EUA would enable timely access to this effective treatment option.
    • Strengthening the Arsenal: By recognizing the importance of cefepime/zidebactam and expediting its EUA, India can strengthen its arsenal against drug-resistant infections. This Indian innovation can contribute significantly to addressing the global challenge of drug resistance.
    • Potential Global Impact: Granting EUA for cefepime/zidebactam not only saves lives within India but also extends a helping hand globally to countless individuals in desperate need of effective treatment options. India’s scientific achievements can make a substantial impact on the world stage.
    • Scientific Prowess: Cefepime/zidebactam stands as a shining example of India’s scientific prowess in the field of antibiotic development. It showcases the nation’s ability to innovate and provide solutions to combat drug-resistant infections.

    The Dire Situation and the Devastating Reality

    • Scarcity of Potent Antibiotics: The dire situation arises from the scarcity of potent antibiotics to combat highly drug-resistant infections. The available antibiotics have lost their effectiveness due to rising resistance, leaving healthcare professionals with limited treatment options.
    • Lives at Risk: The devastating reality is that countless lives are at risk due to inadequate antibiotics. Patients, particularly those who are critically ill or immunocompromised, are succumbing to infections that were once treatable. This results in significant morbidity and mortality rates.
    • Ineffectiveness of Current Antibiotics: Rising drug resistance has rendered once-effective antibiotics ineffective against formidable pathogens. The constant evolution and mutation of bacteria pose a significant challenge to doctors in providing effective treatment.
    • Multifaceted Challenges: Doctors face multifaceted challenges in combating drug-resistant infections. They must navigate through a shrinking arsenal of effective antibiotics, leading to limited choices and the use of suboptimal treatments. This situation adds immense pressure and helplessness to doctors on the front lines.
    • High Death Toll: The dire situation and devastating reality contribute to a high death toll attributed to drug-resistant infections. Millions of lives are lost each year due to the inadequacy of available antibiotics in effectively treating these formidable pathogens.
    • Race Against Time: Healthcare professionals are constantly racing against time, trying to stay one step ahead of mutating bacteria. The urgency to find effective solutions and the frustration of not having access to life-saving antibiotics in critical situations weigh heavily on doctors.
    • Global Concern: The dire situation and devastating reality of drug-resistant infections are a global concern. It requires collaborative efforts from healthcare authorities, policymakers, researchers, and pharmaceutical companies to address the challenge and develop effective solutions.

    What is Emergency Use Authorization (EUA)?

    • EUA is a regulatory pathway that allows for the expedited authorization and use of medical products during public health emergencies.
    • Under EUA, medical products, including vaccines, therapeutics, and diagnostics, can be made available for use in emergency situations before they receive full approval or licensure. This allows for a more rapid response to public health crises, such as outbreaks or pandemics, by providing access to potentially life-saving interventions.
    • EUA involves a rigorous evaluation process by regulatory authorities, who assess the available scientific evidence, safety data, and potential benefits and risks of the medical product.

    The Urgent Need for EUA

    • Limited Treatment Options: In the face of highly drug-resistant infections, the available treatment options become limited and often ineffective. Conventional antibiotics may not be effective against these infections, leading to prolonged illness and increased mortality rates.
    • Life-Threatening Infections: Drug-resistant infections can pose significant risks to patients’ lives, especially those who are immunocompromised or critically ill. Immediate access to effective treatments is crucial to combat these infections and improve patient outcomes.
    • Time-Sensitive Situations: In some cases, time is of the essence, and delays in accessing effective treatments can have severe consequences. EUA allows for expedited authorization and access to potentially life-saving interventions in emergency situations.
    • Addressing Public Health Emergencies: EUA plays a crucial role in responding to public health emergencies, such as outbreaks or pandemics, where swift action is needed to deploy interventions that can save lives and mitigate the spread of infections.
    • Balancing Safety and Efficacy: While EUA expedites access to treatments, safety and efficacy remain critical considerations. Rigorous evaluation and monitoring are essential to ensure that authorized treatments meet the necessary standards for patient safety and effectiveness.
    • Supporting Research and Development: EUA can provide a pathway for essential treatments that are still in clinical trials to be made available to patients who have no other viable options. This allows for the collection of real-world data and insights that can further inform research and development efforts.
    • Global Collaboration: EUA for essential treatments can also enable collaboration and sharing of knowledge and resources on a global scale. It allows countries to work together in addressing public health challenges and ensures equitable access to life-saving interventions.

    Conclusion

    • The story of the 18-year-old patient’s recovery highlights the critical need for Emergency Use Authorization for essential antibiotics. The scarcity of potent antibiotics and the rising threat of drug-resistant infections demand urgent action. By granting EUA for promising antibiotics like cefepime/zidebactam and cefiderocol, we can save lives and make a significant impact globally. It is time for India to demonstrate its scientific prowess and commitment to combatting the challenges posed by drug-resistant infections